The acquisition of said brands will expand Lupin’s portfolio of inhalation products
Lupin informed that its wholly owned subsidiary Lupin, USA, is acquiring all assets required to manufacture and commercialise Brovana (Arformoterol Tartrate) Inhalation Solution and Xopenex HFA (Levalbuterol Tartrate) Inhalation Aerosol in the US.
The acquisition of said brands will expand Lupin’s portfolio of inhalation products. The company stated that the acquisition is expected to be completed two to three weeks post-signing.
Lupin will acquire the said brands for $75 million (approx Rs622.40 crore).
“We remain focussed on growing our respiratory business in the United States,” said Lupin, CEO, Vinita Gupta. With the launch of Albuterol MDI and Brovana-approved generics, we have built a solid position in the respiratory category. The inclusion of these two brands strengthens our market position.”
Brovana can be used for the long-term maintenance therapy of bronchoconstriction in individuals suffering from chronic obstructive pulmonary diseases, such as chronic bronchitis and emphysema.
Xopenex HFA is a beta2-adrenergic agonist (SABA) with a short half-life intended for the treatment or prevention of bronchospasm in adults, adolescents, and children four years of age and older with reversible obstructive airway disease.